Physician profile
Raviinder Mann
NPI 1124381637
$23,034.77
in general payments reported to CMS, 2019-2025
39 companies · $4,905 in 2025
The $4,905 reported for 2025 was more than what 83% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $847 · 2021: $4,720 · 2022: $2,614 · 2023: $5,453 · 2024: $3,811 · 2025: $4,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $2,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,331.51 |
| Travel and Lodging | $2,838.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $6,221.78 | 2020-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $4,229.87 | 2019-2025 | Triclip, Mitraclip, Jeti |
| Medtronic, INC. | $2,483.04 | 2021-2025 | Corevalve Evolut R, Abre, Resolute Onyx |
| Inari Medical, INC. | $1,745.30 | 2020-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $1,584.54 | 2020-2025 | Watchman Flx, Watchman Access System, General - Therapies |
| Abiomed | $906.54 | 2022-2025 | Impella |
| Kestra Medical Technology Services, INC. | $744.28 | 2023-2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $664.17 | 2020-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $467.93 | 2022-2023 | Optimizer |
| Penumbra, INC. | $405.38 | 2023-2025 | Indigo System |
| Medtronic Vascular, INC. | $395.96 | 2019-2020 | |
| Cardiva Medical, INC. | $361.72 | 2022-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Optowire, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| E.R. Squibb & Sons, L.L.C. | $356.66 | 2021-2025 | Camzyos, Eliquis |
| Cleerly, INC. | $299.27 | 2024-2025 | Cleerly Ischemia, Cleerly Labs |
| Astrazeneca Pharmaceuticals LP | $291.73 | 2021-2024 | Lokelma, Andexxa |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raviinder Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.